Physician profile
Muhammad Rais
NPI 1306883376
$15,994.05
in general payments reported to CMS, 2019-2025
37 companies · $3,448 in 2025
The $3,448 reported for 2025 was more than what 82% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,858 · 2020: $903 · 2021: $1,960 · 2022: $2,581 · 2023: $2,148 · 2024: $3,097 · 2025: $3,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,444 · Consulting Fee: $150 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,443.56 |
| Consulting Fee | $150.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,680.20 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,580.93 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $2,447.40 | 2019-2025 | Dupixent |
| Genzyme Corporation | $841.35 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $612.32 | 2025 | Neffy |
| Csl Behring | $544.85 | 2019-2025 | Hizentra, Andembry |
| Novartis Pharmaceuticals Corporation | $472.23 | 2019-2025 | |
| Amgen INC. | $465.57 | 2021-2025 | Tezspire |
| Jazz Pharmaceuticals INC. | $462.18 | 2019-2025 | |
| Pfizer INC. | $434.05 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $377.05 | 2020-2023 | Airduo Digihaler |
| Genentech USA, INC. | $311.45 | 2019-2021 | |
| Grifols USA, LLC | $280.11 | 2019-2024 | Xembify |
| Kaleo, INC. | $279.61 | 2019-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $267.63 | 2020-2025 | Takhzyro, Glassia |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $192.15 | 2021-2025 | Orladeyo |
| Blueprint Medicines Corporation | $175.93 | 2024 | Ayvakit |
| Pharming Healthcare, INC. | $168.31 | 2023-2025 | Joenja, Ruconest |
| Harmony Biosciences LLC | $164.59 | 2024-2025 | |
| Galderma Laboratories, L.P. | $161.14 | 2025 | Nemluvio |
| Avadel Cns Pharmaceuticals, LLC | $150.00 | 2024 | Lumryz |
| Incyte Corporation | $146.88 | 2022 | |
| Seagen INC. | $125.00 | 2021 | |
| Rigel Pharmaceuticals, INC. | $117.90 | 2019 | |
| Aimmune Therapeutics, INC. | $77.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.41 | 2019-2021 | |
| Philips North America LLC | $59.05 | 2019 | |
| Sanofi-Aventis U.S. LLC | $57.48 | 2022 | |
| Greer Laboratories, INC. | $49.67 | 2021-2024 | Oralair |
| Phathom Pharmaceuticals, INC. | $44.84 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $33.62 | 2019-2023 | |
| Lilly USA, LLC | $32.72 | 2025 | Zepbound |
| Resmed Corp | $28.66 | 2020-2025 | |
| Eyevance Pharmaceuticals LLC | $24.56 | 2021 | |
| Hikma Pharmaceuticals USA | $21.83 | 2024 | Ryaltris |
| Circassia INC. | $17.47 | 2019 | |
| Shire North American Group INC | $16.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Rais listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.